Making effective decisions in health care requires a thorough understanding of the patient perspective, as well as robust, precise measures of response to therapy. The Patient Access & Affordability Project evaluates the various frameworks used to assess and demonstrate the value of new treatments to ensure that the patient is kept at the center of health care decisions.
The Latest Insights
Supreme Court Passes on Skinny Labeling Case: What Does This Mean for Patients?
In mid-May, the U.S. Supreme Court opted not to take up a patent-infringement case between two pharmaceutical companies – Teva and GlaxoSmithKline (GSK). While it largely went unnoticed among those who are not patent lawyers, IP nerds, or drug companies, the decision’s ripple effects could have a negative impact for patients across the country looking to get access to newer, better treatments.
FROM OUR ADVISORY BOARD: Are We On the Cusp of a New Drug Pricing Paradigm?
We may be on the verge of a titanic shift in how drug prices are set. It’s been led by a dramatic decline in insulin prices, but it’s spreading to other brand drugs as well. This new paradigm is the unintended but welcome result of legislative, regulatory, and market pressures exerted on the biopharmaceutical industry.
OP-ED: Promising New Alzheimer’s Drug Calls for CMS to Rethink Access Restrictions .
Some of the most exciting advances in science and medicine are happening in Alzheimer’s, a disease that is one of the greatest epidemics of this generation. Eli Lilly announced promising results last week for experimental amyloid-targeting drug donanemab. These clinical trial results showed that the drug can slow cognitive and functional decline for people with early-stage Alzheimer’s disease.
Group Purchasing Organizations Impact Access to Medications, Increase Drug Shortages
Drug shortages can be a matter of life and death. Sometimes, a shortage may simply require patients to temporarily pay a higher price or shop around to different local pharmacies to find one that has their prescription in stock. But, in the worst cases, a shortage means patients are entirely unable get access to a potentially lifesaving drug at any price.
State and Federal Governments Continue to Challenge PBM Business Model
Ohio the latest state to legally challenge the business model of Pharmacy Benefit Mangers (PBMs). Last month, the state’s attorney general filed a landmark lawsuit alleging that Express Scripts and Prime Therapeutics – two of the country’s largest PBMs – illegally...
OP-ED: The Cold War at HHS
by MacKay Jimeson There is an interagency cold war between the Food and Drug Administration and the Centers for Medicare and Medicaid Services at the Department of Health and Human Services. FDA wants to approve promising treatments for patients faster. CMS...
PRESS RELEASE: Patients Rising Announces Advisory Board for Patient Access & Affordability Project
Leading experts in public policy, economics, and science will focus on the rare and chronic disease plight before lawmakers, regulators and insurers. WASHINGTON — Patients Rising, a non-profit organization advocating on behalf of patients with chronic and rare...
The Alzheimer’s Dilemma: Government and Private Payers Must Evolve or Die
By MacKay Jimeson In a proclamation last year, President Joe Biden said, “in the next 30 years, the number of Americans with Alzheimer’s is expected to reach nearly 14 million, straining families and our health care system. Fortunately, we are on the cusp of...
This Rare Disease Day we need to go beyond raising awareness and move towards tangible policy and regulatory action.
By MacKay Jimeson Too many patients and families are in crisis as we mark another Rare Disease Day. Policymakers are focused on debates on Accelerated Approval and drug pricing, while many patients are without treatment due to regulatory or insurance coverage...
PRESS RELEASE: Patient Group Releases Special Report on Biosimilar Market and Trends
New report analyzes patient impact of game-changing biosimilars, including the introduction of competing biosimilars for Humira WASHINGTON — Patients Rising, a non-profit organization advocating on behalf of patients with chronic and rare diseases, today released its...
Get Updates in Your Inbox
Sign Up. Stay Informed.